Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

NCT00836914 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Rhinitis

Interventions

DRUG: CAL-101
DRUG: Placebo

Sponsor

Gilead Sciences